|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008976,
umls-concept:C0018787,
umls-concept:C0021308,
umls-concept:C0030705,
umls-concept:C0155626,
umls-concept:C0205225,
umls-concept:C0205421,
umls-concept:C0456389,
umls-concept:C0522523,
umls-concept:C0917874,
umls-concept:C1174136,
umls-concept:C1522318,
umls-concept:C1627358,
umls-concept:C1948041,
umls-concept:C2349975
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2010-2-4
|
|
pubmed:databankReference |
|
|
pubmed:abstractText |
The purpose of the study was to understand determinants of infarct size in a primary percutaneous intervention (PCI) population treated with pexelizumab compared with placebo.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
1876-7591
|
|
pubmed:author |
pubmed-author:ArmstrongPaul WPW,
pubmed-author:BarsnessGregory WGW,
pubmed-author:DillThorstenT,
pubmed-author:GrangerChristopher BCB,
pubmed-author:HammChristian WCW,
pubmed-author:KimRaymond JRJ,
pubmed-author:PatelManesh RMR,
pubmed-author:RademakersFrank EFE,
pubmed-author:StebbinsAmandaA,
pubmed-author:ValetiUma SUS,
pubmed-author:Van de WerfFransF,
pubmed-author:VelletiUma SUS,
pubmed-author:WorthleyStephen GSG
|
|
pubmed:copyrightInfo |
Copyright (c) 2010 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
3
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
52-60
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:20129531-Aged,
pubmed-meshheading:20129531-Angioplasty, Balloon, Coronary,
pubmed-meshheading:20129531-Antibodies, Monoclonal,
pubmed-meshheading:20129531-Antibodies, Monoclonal, Humanized,
pubmed-meshheading:20129531-Australia,
pubmed-meshheading:20129531-Cardiovascular Agents,
pubmed-meshheading:20129531-Chi-Square Distribution,
pubmed-meshheading:20129531-Coronary Circulation,
pubmed-meshheading:20129531-Europe,
pubmed-meshheading:20129531-Female,
pubmed-meshheading:20129531-Humans,
pubmed-meshheading:20129531-Linear Models,
pubmed-meshheading:20129531-Magnetic Resonance Imaging, Cine,
pubmed-meshheading:20129531-Male,
pubmed-meshheading:20129531-Middle Aged,
pubmed-meshheading:20129531-Myocardial Infarction,
pubmed-meshheading:20129531-Myocardium,
pubmed-meshheading:20129531-North America,
pubmed-meshheading:20129531-Predictive Value of Tests,
pubmed-meshheading:20129531-Risk Assessment,
pubmed-meshheading:20129531-Risk Factors,
pubmed-meshheading:20129531-Single-Chain Antibodies,
pubmed-meshheading:20129531-Stroke Volume,
pubmed-meshheading:20129531-Time Factors,
pubmed-meshheading:20129531-Treatment Outcome,
pubmed-meshheading:20129531-Ventricular Function, Left
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Pexelizumab and infarct size in patients with acute myocardial infarction undergoing primary percutaneous coronary Intervention: a delayed enhancement cardiac magnetic resonance substudy from the APEX-AMI trial.
|
|
pubmed:affiliation |
Duke University, Durham, North Carolina 27710, USA. manesh.patel@duke.edu
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
